JP2017528464A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528464A5
JP2017528464A5 JP2017513207A JP2017513207A JP2017528464A5 JP 2017528464 A5 JP2017528464 A5 JP 2017528464A5 JP 2017513207 A JP2017513207 A JP 2017513207A JP 2017513207 A JP2017513207 A JP 2017513207A JP 2017528464 A5 JP2017528464 A5 JP 2017528464A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
cell
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528464A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049235 external-priority patent/WO2016040515A1/en
Publication of JP2017528464A publication Critical patent/JP2017528464A/ja
Publication of JP2017528464A5 publication Critical patent/JP2017528464A5/ja
Pending legal-status Critical Current

Links

JP2017513207A 2014-09-10 2015-09-09 置換ピペリジン化合物 Pending JP2017528464A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462048771P 2014-09-10 2014-09-10
US62/048,771 2014-09-10
US201462078845P 2014-11-12 2014-11-12
US62/078,845 2014-11-12
US201562146790P 2015-04-13 2015-04-13
US62/146,790 2015-04-13
PCT/US2015/049235 WO2016040515A1 (en) 2014-09-10 2015-09-09 Substituted piperidine compounds

Publications (2)

Publication Number Publication Date
JP2017528464A JP2017528464A (ja) 2017-09-28
JP2017528464A5 true JP2017528464A5 (enExample) 2018-10-18

Family

ID=55459535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513207A Pending JP2017528464A (ja) 2014-09-10 2015-09-09 置換ピペリジン化合物

Country Status (13)

Country Link
US (1) US10577363B2 (enExample)
EP (1) EP3193605A4 (enExample)
JP (1) JP2017528464A (enExample)
KR (1) KR20170047397A (enExample)
CN (1) CN107072207A (enExample)
AU (1) AU2015315182A1 (enExample)
BR (1) BR112017004589A2 (enExample)
CA (1) CA2960280A1 (enExample)
EA (1) EA201790327A1 (enExample)
IL (1) IL250888A0 (enExample)
MX (1) MX2017002986A (enExample)
SG (2) SG11201701597RA (enExample)
WO (1) WO2016040515A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
CA2960274A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
AU2015315174B2 (en) 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
US10106509B2 (en) * 2015-02-27 2018-10-23 Op Bio Factory Co., Ltd. Method for producing kakeromycin and derivatives thereof
EP3490986B1 (en) 2016-07-28 2021-11-24 Idorsia Pharmaceuticals Ltd Piperidine cxcr7 receptor modulators
WO2018151678A1 (en) * 2017-02-15 2018-08-23 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics
KR102502046B1 (ko) * 2018-01-26 2023-02-20 이도르시아 파마슈티컬스 리미티드 Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-{[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노}-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태
JP7425793B2 (ja) 2018-10-29 2024-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
CA3112510A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
WO2021065898A1 (ja) 2019-09-30 2021-04-08 日本ケミファ株式会社 アゼパン誘導体
CN114702552B (zh) * 2022-03-11 2024-05-31 苏州思萃免疫技术研究所有限公司 mTORC2抑制剂
CN117800895A (zh) * 2022-09-30 2024-04-02 苏州阿尔脉生物科技有限公司 草酸胺类衍生物、包含其的药物组合物及其医药用途
WO2025133989A1 (en) * 2023-12-20 2025-06-26 Alt-Bio Pte. Ltd. Smyd modulators and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228288B (it) * 1989-01-09 1991-06-07 Zambon Spa Composti ad attivita' antiserotoninica
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SE0403106D0 (sv) * 2004-12-20 2004-12-20 Astrazeneca Ab Chemical compounds
WO2008137834A2 (en) * 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
WO2009072643A1 (en) * 2007-12-03 2009-06-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
PL2651417T3 (pl) * 2010-12-16 2017-08-31 Calchan Limited Pochodne pirolopirymidyny hamujące ASK1
JP2017527577A (ja) 2014-09-10 2017-09-21 エピザイム,インコーポレイティド 置換ピロリジン化合物
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
AU2015315174B2 (en) 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
CA2960274A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
EP3193609A4 (en) 2014-09-10 2018-02-28 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds

Similar Documents

Publication Publication Date Title
JP2017527577A5 (enExample)
JP2017538659A5 (enExample)
CN115485277B (zh) 作为HER2抑制剂的[1,3]二嗪基[5,4-d]嘧啶
JP6884102B2 (ja) がんの治療のための化合物
JP2024138293A (ja) バイオマーカー型治療用組成物
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
JP2016514695A5 (enExample)
Chen et al. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl) phenyl) amino) pyrimidin-2-yl) amino)-4-methoxy-2-(4-methyl-1, 4-diazepan-1-yl) phenyl) acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC
JP2023512174A (ja) HER2阻害薬としての[1,3]ジアジノ[5,4-d]ピリミジン
EP4100412A1 (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
JP5323289B1 (ja) 新規ピペリジン化合物又はその塩
MA40581A (fr) Dérivés pyridone utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
JP2019514950A5 (enExample)
JP2011515397A5 (enExample)
EA201391319A1 (ru) Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
CA3094449A1 (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
ES2980476T3 (es) Derivados de tienopiridina y composición farmacéutica que los contiene
JP2015518894A5 (enExample)
MY191936A (en) Serine/threonine kinase inhibitors
JP2015518899A5 (enExample)
JP2017527577A (ja) 置換ピロリジン化合物
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
TW201245177A (en) Quinolyl amines as kinase inhibitors
CA2899968A1 (en) Substituted 2-aminopyridine protein kinase inhibitor
JP2017528461A5 (enExample)